Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Dezember 2025 04:00 ET | Quelle: AKAMPION

Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy

Mabylon has initiated a Phase I clinical trial evaluating its novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy.
12. August 2025 04:00 ET | Quelle: AKAMPION

Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept

Funding combines equity investment and convertible loanFocus on best-in-class, clinical-stage peanut allergen neutralizing antibody Further potential for developing Mabylon’s discovery and...
24. September 2024 04:00 ET | Quelle: AKAMPION

Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs

Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has...